Ascletis ASC30 U.S. Phase IIa Obesity Study Reaches Full Enrollment
October 20, 2025 | 16:13
Once-monthly depot formulation targets adherence barriers; investigators will now examine whether small-molecule GLP-1 agonists can match peptide efficacy without cold-chain burden.
Ascletis ASC30 GLP-1R Data 2025: Oral Obesity Drug Cuts Weight Twelve Per Cent
September 17, 2025 | 15:58
Once daily pill rivals injectables, giving diabetes bloggers EASD 2025 keywords and a full poster PDF for search friendly coverage.
Ascletis pill shows once-daily PK win
August 28, 2025 | 18:28
Obesity patients cheer one-tablet hope—yet regulators await Phase III waistlines.
Ascletis presents new data on ASC30 and ASC47 at ADA 2025
June 09, 2025 | 13:00
Promising diabetes treatment results to be showcased at major U.S. scientific forum.
Ascletis Reports Positive U.S. Phase Ib Results for ASC30, Submits Phase IIa Protocol to FDA
April 23, 2025 | 09:00
A promising new player in metabolic disease, ASC30 shows early potential as Ascletis advances into next-phase trials.
Mobile Version